BCV
SMMT icon

Banque Cantonale Vaudoise’s Summit Therapeutics SMMT Stock Holding History

Banque Cantonale Vaudoise’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367 Buy
25,195
+1,279
+5% +$22.7K ﹤0.01% 567
2026
Q1 		$453K Buy
+23,916
New +$387K 0.02% 509

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Banque Cantonale Vaudoise's SMMT Position: Q2 2026 in Review

Banque Cantonale Vaudoise increased its Summit Therapeutics (SMMT) stake by 5.3% in Q2 2026, buying an estimated $22.7K and bringing the position to 25,195 shares worth $367. The position accounts for ﹤0.01% of the portfolio, ranked #567.

Banque Cantonale Vaudoise first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $453K in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Banque Cantonale Vaudoise held 25,195 shares of Summit Therapeutics worth $367 as of Q2 2026.
  • Banque Cantonale Vaudoise bought 1,279 Summit Therapeutics shares in Q2 2026, an estimated $22.7K.
  • Summit Therapeutics made up ﹤0.01% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #567 holding.
  • Banque Cantonale Vaudoise first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Banque Cantonale Vaudoise's Summit Therapeutics position peaked at $453K in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.